A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease

被引：218

作者：

Karran, Eric ^{[1
,2
,3
]}

Hardy, John ^{[2
,3
]}

机构：

[1] Alzheimers Res UK, Cambridge CB21 6AD, England

[2] Reta Lila Weston Labs, London, England

[3] UCL, Dept Mol Neurosci, London, England

来源：

ANNALS OF NEUROLOGY | 2014年 / 76卷 / 02期

基金：

英国惠康基金;

关键词：

GAMMA-SECRETASE INHIBITOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSGENIC MOUSE MODEL; BETA IN-VIVO; A-BETA; CEREBROSPINAL-FLUID; COGNITIVE IMPAIRMENT; R-FLURBIPROFEN; PEPTIDE; IMMUNIZATION;

D O I：

10.1002/ana.24188

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：185 / 205

页数：21

共 134 条

[1] Dynamics of Aβ Turnover and Deposition in Different β-Amyloid Precursor Protein Transgenic Mouse Models Following γ-Secretase Inhibition [J].

Abramowski, Dorothee ;

Wiederhold, Karl-Heinz ;

Furrer, Ulrich ;

Jaton, Anne-Lise ;

Neuenschwander, Anton ;

Runser, Marie-Josephine ;

Danner, Simone ;

Reichwald, Julia ;

Ammaturo, Domenico ;

Staab, Dieter ;

Stoeckli, Markus ;

Rueeger, Heinrich ;

Neumann, Ulf ;

Staufenbiel, Matthias .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (02) :411-424

[2] A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease [J].

Aisen, P. S. ;

Saumier, D. ;

Briand, R. ;

Laurin, J. ;

Gervais, F. ;

Tremblay, P. ;

Garceau, D. .

NEUROLOGY, 2006, 67 (10) :1757-1763

[3] Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) [J].

Aisen, Paul S. ;

Gauthier, Serge ;

Ferris, Steven H. ;

Saumier, Daniel ;

Haine, Denis ;

Garceau, Denis ;

Anh Duong ;

Suhy, Joyce ;

Oh, Joonmi ;

Lau, Wan C. ;

Sampalis, John .

ARCHIVES OF MEDICAL SCIENCE, 2011, 7 (01) :102-111

[4]

Alzheimer A., 1907, Zentrabl, Nervenheilk., V30, P177

[5] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].

Andreasen, N ;

Hesse, C ;

Davidsson, P ;

Minthon, L ;

Wallin, A ;

Winblad, B ;

Vanderstichele, H ;

Vanmechelen, E ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 1999, 56 (06) :673-680

[6] Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology [J].

Arvanitakis, Z. ;

Grodstein, F. ;

Bienias, J. L. ;

Schneider, J. A. ;

Wilson, R. S. ;

Kelly, J. F. ;

Evans, D. A. ;

Bennett, D. A. .

NEUROLOGY, 2008, 70 (23) :2219-2225

[7] Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease [J].

Bacher, Michael ;

Depboylu, Candan ;

Du, Yansheng ;

Noelker, Carmen ;

Oertel, Wolfgang H. ;

Behr, Thomas ;

Henriksen, Gjermund ;

Behe, Martin ;

Dodel, Richard .

NEUROSCIENCE LETTERS, 2009, 449 (03) :240-245

[8]

Bacskai BJ, 2002, J NEUROSCI, V22, P7873

[9] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].

Bard, F ;

Cannon, C ;

Barbour, R ;

Burke, RL ;

Games, D ;

Grajeda, H ;

Guido, T ;

Hu, K ;

Huang, JP ;

Johnson-Wood, K ;

Khan, K ;

Kholodenko, D ;

Lee, M ;

Lieberburg, I ;

Motter, R ;

Nguyen, M ;

Soriano, F ;

Vasquez, N ;

Weiss, K ;

Welch, B ;

Seubert, P ;

Schenk, D ;

Yednock, T .

NATURE MEDICINE, 2000, 6 (08) :916-919

[10] Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice [J].

Bard, Frederique ;

Fox, Michael ;

Friedrich, Stuart ;

Seubert, Peter ;

Schenk, Dale ;

Kinney, Gene G. ;

Yednock, Ted .

EXPERIMENTAL NEUROLOGY, 2012, 238 (01) :38-43

← 1 2 3 4 5 6 7 8 9 10 →